2.5 | | MRPS7 | 'CD3 and CD28' vs 'none' | compound, disease | Transcription profiling by array of human CD3-positive T cells from patients with systemic lupus erythematosus |
-2.4 | | MRPS7 | 'P-bodies (cytosolic RNP granules)' vs 'pre-sorted fraction' | fraction | RNA-Seq of purified P-bodies from HEK293 cells |
-2.4 | | MRPS7 | 'kidney transplant; transplant rejection; borderline' vs 'none; normal; none' | clinical information, disease, disease staging | Expression of the IL-17/Th17 axis in the development of acute renal allograft rejection |
-2.3 | | MRPS7 | 'systemic-onset juvenile idiopathic arthritis; placebo, Prednisone, non-steroidal anti-inflammatory drug, methotrexate' vs 'normal; none' | disease, treatment | Gene expression data of whole blood of systemic juvenile idiopathic arthritis (SJIA) patients treated with canakinumab or placebo and age matched healthy controls |
2.2 | | MRPS7 | 'T-helper 1 polarising' at '1 day' vs 'no stimulus' | cell type, sampling time point, stimulus | Transcription profiling by array of human CD4+T-cells, Th1/Th2 polarized time-series and primary memory subsets |
-2.2 | | MRPS7 | 'transplant rejection; borderline' vs 'normal; none' in 'kidney transplant' | clinical information, disease, disease staging | Expression of the IL-17/Th17 axis in the development of acute renal allograft rejection |
2.1 | | MRPS7 | 'Human gammaherpesvirus 4' at '2 day' vs 'none' at '0 day' | infect, time | Infection of naïve primary human B-lymphocytes with Epstein-Barr virus (EBV) – time course transcriptomic analysis in the pre-latent phase of viral infection |
2.1 | | MRPS7 | 'Human gammaherpesvirus 4' at '3 day' vs 'none' at '0 day' | infect, time | Infection of naïve primary human B-lymphocytes with Epstein-Barr virus (EBV) – time course transcriptomic analysis in the pre-latent phase of viral infection |
-2.1 | | MRPS7 | 'tumor necrosis factor alpha' vs 'none' in 'brain microvascular endothelial cell; co-culture' | cell type, growth condition, stimulus | Reactive astrocytes transduce blood-brain barrier inflammation through a TNFα-STAT3 signaling axis and secretion of alpha 1-antichymotrypsin |
-2 | | MRPS7 | 'tumor necrosis factor alpha' vs 'none' in 'brain microvascular endothelial cell; monoculture' | cell type, growth condition, stimulus | Reactive astrocytes transduce blood-brain barrier inflammation through a TNFα-STAT3 signaling axis and secretion of alpha 1-antichymotrypsin |
2 | | MRPS7 | 'T-helper 2 polarising' at '1 day' vs 'no stimulus' | cell type, sampling time point, stimulus | Transcription profiling by array of human CD4+T-cells, Th1/Th2 polarized time-series and primary memory subsets |
2 | | MRPS7 | '4-hydroxy-3-methyl-but-2-enyl pyrophosphate; 1 nanomolar' vs 'none' | compound | Transcription profiling by array of human peripheral blood gamma-delta T cells stimulated with HMB-PP or OKT-3 |
-2 | | MRPS7 | 'Newcastle disease virus' at '14 hour' vs 'none' at '0 hour' | infect, time | Transcription profiling by array of human dendritic cells infected with Newcastle Disease Virus |
-1.9 | | MRPS7 | 'teratozoospermia' vs 'normospermic' | disease | Transcription profiling by array of human sperm from normospermic and teratozoospermic individuals |
-1.9 | | MRPS7 | 'Newcastle disease virus' at '18 hour' vs 'none' at '0 hour' | infect, time | Transcription profiling by array of human dendritic cells infected with Newcastle Disease Virus |
1.9 | | MRPS7 | 'interleukin-21 (Homo sapiens); 25 nanogram per milliliter' vs 'control; none' | compound, growth condition | Gene signature of CLL cells cultured with activated T cells or CD40L-expressing cells |
1.8 | | MRPS7 | 'injected in NSG mouse' vs 'none' in 'none' | stimulus, xenograft | RNA-Seq of T cells sorted from human PBMCs, or from T cells stimulated with CD3/CD28 beads for 4 days, or from the spleen of NSG or NSG-HLA-A2/HHD mice, 7 days after transplantation with human PBMCs |
1.8 | | MRPS7 | 'injected in NSG-HLA-A2/HHD mouse' vs 'none' in 'none' | stimulus, xenograft | RNA-Seq of T cells sorted from human PBMCs, or from T cells stimulated with CD3/CD28 beads for 4 days, or from the spleen of NSG or NSG-HLA-A2/HHD mice, 7 days after transplantation with human PBMCs |
1.8 | | MRPS7 | 'Human gammaherpesvirus 4' at '4 day' vs 'none' at '0 day' | infect, time | Infection of naïve primary human B-lymphocytes with Epstein-Barr virus (EBV) – time course transcriptomic analysis in the pre-latent phase of viral infection |
-1.8 | | MRPS7 | 'kidney transplant; transplant rejection; acute' vs 'none; normal; none' | clinical information, disease, disease staging | Expression of the IL-17/Th17 axis in the development of acute renal allograft rejection |
1.8 | | MRPS7 | 'anti-CD3 antibody; 1 microgram per milliliter' vs 'none' | compound | Transcription profiling by array of human peripheral blood gamma-delta T cells stimulated with HMB-PP or OKT-3 |
1.8 | | MRPS7 | 'cells p16-transfected' vs 'control' | treatment | Induction of apoptotic processes in Capan-1 pancreatic carcinoma cells by restoration of p16INK4a expression |
-1.7 | | MRPS7 | '5-amino-1-(5-phospho-D-ribosyl)imidazole-4-carboxamide; 0.4 millimolar' vs 'none' | compound | Transcriptome of primary acute myeloid leukemia (AML) cells treated with AICAr |
-1.7 | | MRPS7 | 'blood alcohol content 0.02%declining' vs 'control' in 'time point 5' | sampling time point, treatment | Microarray characterization of gene expression changes in blood during acute ethanol exposure |
-1.7 | | MRPS7 | 'transplant rejection; acute' vs 'normal; none' in 'kidney transplant' | clinical information, disease, disease staging | Expression of the IL-17/Th17 axis in the development of acute renal allograft rejection |
-1.7 | | MRPS7 | 'gestational week 11 to 13' vs 'adult' in 'normal' | developmental stage, phenotype | Comparison of global gene expression profiles of microdissected human foetal Leydig cells with their normal and hyperplastic adult equivalents |
-1.7 | | MRPS7 | 'Newcastle disease virus' at '16 hour' vs 'none' at '0 hour' | infect, time | Transcription profiling by array of human dendritic cells infected with Newcastle Disease Virus |
-1.6 | | MRPS7 | 'formalin-fixed,parafin-embedded xenograft; messageAmp Premier methodology' vs 'fresh-frozen xenograft; normal' | infect, specimen with known storage state, treatment | A Methodology for Utilization of Predictive Genomic Signatures in FFPE Samples |
1.6 | | MRPS7 | 'stimulation' vs 'control' | growth condition | Effect of human breast tumor supernatant on normal CD4+ T cells (Confirmation Set SN) |
-1.6 | | MRPS7 | '7 day' vs '3 day' in 'hypoxia' | environmental stress, time | Transcription profiling by array of the effect of hypoxia in tumour-initiating cells derived from a colorectal cancer patient |
-1.6 | | MRPS7 | 'herpes simplex virus G207' vs 'none' | infect | Transcription profiling by array of human malignant peripheral nerve sheath tumor cells after infection with herpes simplex virus G207 |
1.6 | | MRPS7 | 'lung cancer' vs 'normal' in 'lung; Fresh-frozen tissue' | disease, organism part, protocol | Transcription profiling by array of formalin-fixed paraffin-embedded or fresh frozen human tumor samples |
-1.6 | | MRPS7 | 'Francisella tularensis novicida' vs 'uninfected' | infect | Transcription profiling by array of human peripheral blood mononuclear cells infected with Francisella tularensis |
-1.6 | | MRPS7 | 'arsenite' vs 'control' | compound | Transcription profiling by high throughput sequencing of 293S cells treated with arsenite |
1.5 | | MRPS7 | 'cisplatin; 100 micromolar' vs 'none' in 'scrambled siRNA' | RNA interference, compound | RNA-seq of human head and neck cancer cell line SQD9 knock-out for TMEM45A exposed to cisplatin |
1.5 | | MRPS7 | 'Human gammaherpesvirus 4' at '1 day' vs 'none' at '0 day' | infect, time | Infection of naïve primary human B-lymphocytes with Epstein-Barr virus (EBV) – time course transcriptomic analysis in the pre-latent phase of viral infection |
-1.5 | | MRPS7 | 'poly(I:C); 25 microgram per milliliter' vs 'none' in 'none; none' | compound, infect, stimulus | RNA-seq of H1N1 infected monocyte-derived dendritic cells (MoDC), stimulated with single-stranded oligonucleotides (ssON) and/or Poly I:C. |
-1.5 | | MRPS7 | 'CRISPR-Cas9 induced GNRH1 reporter; 27 day' vs 'wild type genotype; 20 day' | genotype, stimulus, time | RNA-Seq of GNRH1 neurons differentiated from human pluripotent stem cells |
1.5 | | MRPS7 | 'squamous cell carcinoma' vs 'normal' | block, disease | RNA-seq of a panel of non-melanoma skin cancer lesions |
-1.5 | | MRPS7 | 'blood alcohol content 0.08%' vs 'control' in 'time point 3' | sampling time point, treatment | Microarray characterization of gene expression changes in blood during acute ethanol exposure |
-1.5 | | MRPS7 | 'SKR6LR cells resistant to lapanitib' vs 'SKR6 cells with elevated HER2 expression' | phenotype | Nuclear factor kappa B activation-induced anti-apoptosis renders HER2 positive cells drug resistant and accelerates tumor growth |
1.5 | | MRPS7 | 'actinic keratosis' vs 'normal' | block, disease | RNA-seq of a panel of non-melanoma skin cancer lesions |
-1.5 | | MRPS7 | 'hypoxia' vs 'normoxia' at '7 day' | environmental stress, time | Transcription profiling by array of the effect of hypoxia in tumour-initiating cells derived from a colorectal cancer patient |
1.5 | | MRPS7 | 'differentiated macrophage' at '168 hour' vs '0 hour' | time | Transcription profiling of human monocytes to macrophage differentiation |
1.5 | | MRPS7 | 'ovarian cancer' vs 'normal' in 'stromal cell' | cell type, disease | A cancer associated fibroblasts (CAFs) specific gene signature in high grade serous ovarian cancer |
-1.5 | | MRPS7 | 'Newcastle disease virus' at '12 hour' vs 'none' at '0 hour' | infect, time | Transcription profiling by array of human dendritic cells infected with Newcastle Disease Virus |
1.4 | | MRPS7 | 'cisplatin; 100 micromolar' vs 'none' in 'TMEM45A knockdown by siRNA' | RNA interference, compound | RNA-seq of human head and neck cancer cell line SQD9 knock-out for TMEM45A exposed to cisplatin |
1.4 | | MRPS7 | 'KLF17 overexpression' at '24 day' vs 'wild type' at '0 day' | phenotype, time | RNA-seq of hESCs undergoing primed to naive-like resetting via exogenous KLF17 overexpression |
1.4 | | MRPS7 | 'KLF17 overexpression' at '5 day' vs 'wild type' at '0 day' | phenotype, time | RNA-seq of hESCs undergoing primed to naive-like resetting via exogenous KLF17 overexpression |
-1.4 | | MRPS7 | 'blood alcohol content 0.04%declining' vs 'control' in 'time point 4' | sampling time point, treatment | Microarray characterization of gene expression changes in blood during acute ethanol exposure |
1.4 | | MRPS7 | 'MCF-7 clone 5C' vs 'MCF-7' | cell line | Transcription profiling by array of human hormone-responsive MCF-7 cells versus estrogen-deprived breast cancer cells |
-1.4 | | MRPS7 | 'blood alcohol content 0%' vs 'control' in 'time point 1' | sampling time point, treatment | Microarray characterization of gene expression changes in blood during acute ethanol exposure |
-1.4 | | MRPS7 | 'GLV-1h153' at '24 hour' vs 'control' | infect, time | Expression data from human pancreatic cells PANC-1 infected with oncolytic vaccinia virus GLV-1h153 |
1.4 | | MRPS7 | 'T-helper 1 polarising' at '5 days' vs 'no stimulus' | cell type, sampling time point, stimulus | Transcription profiling by array of human CD4+T-cells, Th1/Th2 polarized time-series and primary memory subsets |
1.4 | | MRPS7 | '3 h DRB 8 min 4sU' vs 'untreated' | treatment | 4sUDRB-seq: measuring transcription elongation and initiation genomewide |
1.4 | | MRPS7 | 'non-triple-negative breast cancer; breast carcinoma' vs 'normal' | clinical information, disease | RNA-seq of 17 breast tumor samples of three different subtypes and normal human breast organoids samples |
-1.4 | | MRPS7 | 'freshly isolated' vs 'monolayer' | growth condition | Transcription profiling by array of human mesenchymal stem cells in 2D culture compared with two different alginate-based 3D scaffolds |
-1.4 | | MRPS7 | 'Newcastle disease virus' at '10 hour' vs 'none' at '0 hour' | infect, time | Transcription profiling by array of human dendritic cells infected with Newcastle Disease Virus |
1.4 | | MRPS7 | 'non primary Sjogren syndrome sicca' vs 'normal' | block, disease | Transcription profiling by array of parotid tissue from Primary Sjögren’s Syndrome and controls |
-1.3 | | MRPS7 | '501Mel; shBRG1 knockdown' vs '501Mel; control' | cell line, phenotype | BRG1 recruitment by transcription factors MITF and SOX10 defines a specific configuration of regulatory elements in the melanocyte lineage (RNA-seq) |
1.3 | | MRPS7 | 'KLF17 overexpression' vs 'wild type' at '5 day' | phenotype, time | RNA-seq of hESCs undergoing primed to naive-like resetting via exogenous KLF17 overexpression |
1.3 | | MRPS7 | 'sebaceous of Jadassohn nevus' vs 'normal' | block, disease | RNA-seq of a panel of non-melanoma skin cancer lesions |
-1.3 | | MRPS7 | 'ochratoxin A; 130 nanomolar' vs 'none' at '1 day' | compound, time | Microarray mRNA data of RPTEC/TERT1 cells exposed to nephrotoxic chemicals ochratoxin A and potassium bromate |
-1.3 | | MRPS7 | 'blood alcohol content 0.04%rising' vs 'control' in 'time point 2' | sampling time point, treatment | Microarray characterization of gene expression changes in blood during acute ethanol exposure |
-1.3 | | MRPS7 | 'lipid; 10 volume percent' vs 'control' | compound | Comparison of a macrophage like cell line derived from THP-1 cells |
-1.3 | | MRPS7 | 'Francisella tularensis Schu S4' vs 'uninfected' | infect | Transcription profiling by array of human peripheral blood mononuclear cells infected with Francisella tularensis |
-1.3 | | MRPS7 | "after autologous stem cell transplantation" vs "before autologous stem cell transplantation" | time | RNA-seq of human multiple myeloma patients myeloid-derived suppressor cells (M-MDSC) |
-1.3 | | MRPS7 | 'wild type; BREFELDIN A' vs 'wild type; control' | genotype, treatment | Induction of ER stress in HCT116 colon cancer cells |
1.3 | | MRPS7 | 'cocultured with CD40L- cells' vs 'control' in 'none' | compound, growth condition | Gene signature of CLL cells cultured with activated T cells or CD40L-expressing cells |
1.3 | | MRPS7 | 'RXF 393; poorly differentiated hypernephroma; P10' vs 'RXF 393; poorly differentiated hypernephroma; P0' | cell line, disease, passage | Microarray analysis of xenograft models in use at the Developmental Therapeutics Program of the National Cancer Institute (DTP-NCI) |
-1.2 | | MRPS7 | '11 day' vs '0 day' | time | RNA-Seq characterization of human H1-derived NPC differentiation timecourse |
1.2 | | MRPS7 | 'Influenza A virus (A/California/07-00001/2009(H1N1))' vs 'none' in 'poly(I:C); 25 microgram per milliliter; none' | compound, infect, stimulus | RNA-seq of H1N1 infected monocyte-derived dendritic cells (MoDC), stimulated with single-stranded oligonucleotides (ssON) and/or Poly I:C. |
-1.2 | | MRPS7 | 'breast carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
-1.2 | | MRPS7 | 'PLX4720; 1 micromolar' vs 'none' | compound | RNA-seq of the human melanoma cell-line A375P treated with the BRAF inhibitor PLX4720 and a DMSO control |
1.2 | | MRPS7 | 'astrocyte overexpressing 4 genes' vs 'astrocyte' | phenotype | Transcription profiling by array of human primary astrocytes, cancer stem cells derived from astrocytes overexpressing various oncogenic and iPSC-inducing factors, glioma stem cells and gliblastomat cell line to compare their expression profiles and tumor-initiating capabilities |
1.2 | | MRPS7 | 'NKAES-derived NK cells' vs 'primary human NK cells' in 'none' | clinical history, compound | Transcription profiling by array of human natural killer cells |
-1.1 | | MRPS7 | 'CCNK knock-down' vs 'mock' | RNA interference | RNA-seq analysis of vorinostat-resistant HCT116 cells following gene knockdown of potential vorinostat-resistance candidate genes |
-1.1 | | MRPS7 | 'suberoylanilide hydroxamic acid' vs 'control' | compound | Vascular histone deacetylation by pharmacological HDAC inhibition [SAHA, RNA-seq] |
1.1 | | MRPS7 | 'Human gammaherpesvirus 4' at '14 day' vs 'none' at '0 day' | infect, time | Infection of naïve primary human B-lymphocytes with Epstein-Barr virus (EBV) – time course transcriptomic analysis in the pre-latent phase of viral infection |
-1.1 | | MRPS7 | 'ssON; 0.5 micromolar' vs 'none' in 'none; none' | compound, infect, stimulus | RNA-seq of H1N1 infected monocyte-derived dendritic cells (MoDC), stimulated with single-stranded oligonucleotides (ssON) and/or Poly I:C. |
-1.1 | | MRPS7 | 'miR-221/222' vs 'control' | RNA interference | Gene expression profiling of MCF10A (miR-221/222 vs control) |
1.1 | | MRPS7 | 'tongue squamous cell carcinoma' vs 'normal' in 'vehicle' | compound, disease | Transcription profiling by high throughput sequencing of retinoic acid treated human oral squamous cell carcinoma cells and normal cells |
1.1 | | MRPS7 | '12 hour' vs '0 hour' in 'MCF-10A-H1047R' | cell line, time | Knock-in of PIK3CA-H1047R into MCF-10A |
-1.1 | | MRPS7 | 'shEED' vs 'control' | RNA interference | RNA-seq transcriptional profiling in primary human erythroid progenitor cells upon shRNA-mediated knockdown of PRC2 core subunits |
1.1 | | MRPS7 | 'Human gammaherpesvirus 4' at '5 day' vs 'none' at '0 day' | infect, time | Infection of naïve primary human B-lymphocytes with Epstein-Barr virus (EBV) – time course transcriptomic analysis in the pre-latent phase of viral infection |
-1.1 | | MRPS7 | 'T-cell mediated transplant rejection' vs 'normal' | disease | Intragraft anti-viral-specific gene expression as a distinctive transcriptional signature for polyomavirus-associated nephropathy |
-1.1 | | MRPS7 | 'non-small cell lung carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
-1.1 | | MRPS7 | 'fibroblast; Klinefelter’s Syndrome' vs 'embryonic stem cell; control' | cell type, disease | Expression data of the iPSCs derived from foreskin fibroblast cells of normal person and KS patient |
-1.1 | | MRPS7 | 'colorectal carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
-1.1 | | MRPS7 | 'systemic-onset juvenile idiopathic arthritis; Prednisone, non-steroidal anti-inflammatory drug, methotrexate' vs 'normal; none' | disease, treatment | Gene expression data of whole blood of systemic juvenile idiopathic arthritis (SJIA) patients treated with canakinumab or placebo and age matched healthy controls |
1.1 | | MRPS7 | 'breast cancer; breast' vs 'normal; breast' | disease, organism part | Gene expression profiling of triple negative breast cancer, normal ductal cells, and normal tissues |
1.1 | | MRPS7 | 'Human gammaherpesvirus 4' at '8 day' vs 'none' at '0 day' | infect, time | Infection of naïve primary human B-lymphocytes with Epstein-Barr virus (EBV) – time course transcriptomic analysis in the pre-latent phase of viral infection |
-1.1 | | MRPS7 | 'highly invasive' vs 'poorly invasive' | phenotype | Expression data from CL1-0 and CL1-5 lung cancer cell line. |
1.1 | | MRPS7 | 'low dose IL2' vs 'none' in 'primary human NK cells' | clinical history, compound | Transcription profiling by array of human natural killer cells |
1.1 | | MRPS7 | 'differentiating monocyte' at '16 hour' vs '0 hour' | time | Transcription profiling of human monocytes to macrophage differentiation |
1.1 | | MRPS7 | 'astrocyte overexpressing 7 genes' vs 'astrocyte' | phenotype | Transcription profiling by array of human primary astrocytes, cancer stem cells derived from astrocytes overexpressing various oncogenic and iPSC-inducing factors, glioma stem cells and gliblastomat cell line to compare their expression profiles and tumor-initiating capabilities |
-1.1 | | MRPS7 | 'hepatocellular carcinoma, neoplasm' vs 'normal; normal tissue' in 'liver' | disease, organism part | Transcription profiling by array of normal pancreas, primary pancreatic ductal adenocarcinoma (PDAC), normal liver, and pancreatic liver metastases using the Affymetrix HG-U133A array |
1.1 | | MRPS7 | 'cultured skin substitute; 3 day' vs 'skin; 0 day' | organism part, time | Transcription profiling by array of human grafted engineered skin substitutes |
1.1 | | MRPS7 | 'Epstein-Barr virus infection' vs 'none' in 'palatine tonsil' | infect, organism part | Transcription profiling by array of B cells from tonsils, cord blood and peripheral blood infected with Epstein-Barr virus |
1 | | MRPS7 | 'expression of estrogen receptor beta fused to C terminus tandem affinity purification tag' vs 'expression of estrogen receptor alpha fused to C terminus tandem affinity purification tag' | genotype | The nuclear receptor ERbeta engages AGO2 in regulation of gene transcription, RNA splicing and RISC loading. Part 4 |
-1 | | MRPS7 | 'progenitor cell of endocrine pancreas' vs 'definitive endoderm cell' in 'GATA6 R456C/+; Patient A" | cell line, cell type, genotype, individual | RNA-seq of definitive endoderm and pancreatic progenitor cells derived in vitro from human pluripotent stem cells in order to study the role of transcription factor GATA6 in human pancreas development |
-1 | | MRPS7 | '1 day' vs '0 day' | time | RNA-Seq characterization of human H1-derived NPC differentiation timecourse |
1 | | MRPS7 | 'induced pluripotent stem cell' vs 'fibroblast of dermis' in 'Klinefelter's syndrome' | cell type, disease | Klinefelter syndrome derived hiPSCs show similar XCI behavior as female hPSCs |
-1 | | MRPS7 | 'lapatinib; 500 nanomolar; 7 day' vs 'dimethyl sulfoxide; 1 day' | compound, time | RNA-seq of human oesophageal adenocarcinoma OE19 cell line treated with lapatinib |
-1 | | MRPS7 | 'stimulated with interferon gamma and lipopolysaccharide' vs 'unstimulated' in 'EX00000246' at '24 hour' | compound, time, treatment | GPBAR1 agonism has a broad impact on blocking macrophage activation |
1 | | MRPS7 | '24 hour' vs '0 hour' in 'MCF-10A-H1047R' | cell line, time | Knock-in of PIK3CA-H1047R into MCF-10A |
-1 | | MRPS7 | 'EPZ6438; 10x lowest cytotoxic concentration' vs 'DMSO' in 'SUDHL6' at '6 day' | cell line, compound, time | Expression data from EZH2 inhibitor treated Non-Hodgkins Lymphoma cell lines |
1 | | MRPS7 | 'SR; poorly differentiated B cell origin leukemia; P10' vs 'SR; poorly differentiated B cell origin leukemia; P0' | cell line, disease, passage | Microarray analysis of xenograft models in use at the Developmental Therapeutics Program of the National Cancer Institute (DTP-NCI) |
-1 | | MRPS7 | 'trichostatin A; 500 nanomolar' vs 'control' | compound | Transcription profiling by high throughput sequencing of human aortic endothelial cell treated with TSA |
1 | | MRPS7 | 'deferoxamine; 100 nanomolar echinomycin' vs 'deferoxamine; none' | growth condition, treatment | Transcription profiling by array of human glioblastoma cells after stimulation with deferoxamine and treatment with polyamide 1, echinomycin, or HIF-1a siRNA |
-1 | | MRPS7 | 'deprived of Lysine' vs 'control media' in 'MCF7' at '24 hour' | cell line, growth condition, time | Transcription profiling by array of human MCF-7 and PC3 cells grown under amino acid deprived or rich conditions for 24 or 48 hours |
-1 | | MRPS7 | 'EPZ6438; 10x lowest cytotoxic concentration' vs 'DMSO' in 'KARPAS_422' at '6 day' | cell line, compound, time | Expression data from EZH2 inhibitor treated Non-Hodgkins Lymphoma cell lines |
1 | | MRPS7 | 'atopic eczema; normal skin' vs 'normal; normal skin' | clinical information, disease, phenotype | Transcription profiling by array of acute and chronic atopic dermatitis compared to normal skin |
-1 | | MRPS7 | 'human metapneumovirus' at '48 hour' vs 'none' at '48 hour' | infect, time | Transcription profiling by array of human bronchiole epithelial cells infected with human metapneumovirus |
1 | | MRPS7 | 'erythroleukemia; ZRSR2 shRNA' vs 'normal' | disease, genotype | RNA-seq of bone marrow from patients with myelodysplastic syndrome |
-1 | | MRPS7 | 'human metapneumovirus' at '72 hour' vs 'none' at '48 hour' | infect, time | Transcription profiling by array of human bronchiole epithelial cells infected with human metapneumovirus |
-1 | | MRPS7 | 'Alzheimers disease' vs 'normal' in 'hippocampus' | disease, organism part | Microarray analysis of six brain areas from Alzheimers disease patients and normal individuals |
1 | | MRPS7 | 'astrocyte overexpressing 4 genes' vs 'glioblastoma cell line' | phenotype | Transcription profiling by array of human primary astrocytes, cancer stem cells derived from astrocytes overexpressing various oncogenic and iPSC-inducing factors, glioma stem cells and gliblastomat cell line to compare their expression profiles and tumor-initiating capabilities |
-1 | | MRPS7 | 'PMA' vs 'vehicle' in 'ZXDC1 knockdown' | compound, genotype | Expression data from knockdown of ZXDC1/2 in PMA-treated U937 |
-1 | | MRPS7 | 'aging cells' vs 'spontaneously immortal cells; control' | phenotype, treatment | Pathway Profiling of Replicative and Induced Senescence |
-1 | | MRPS7 | 'TGFbeta3' vs 'control' at '3 day' | growth condition, time | Transcription profiling by array of human bone marrow mesenchymal stem cells after treatment with BMP2 or TGFbeta-3 |
1 | | MRPS7 | 'lesional' vs 'non-lesional' in 'one-cycle cDNA synthesis from bulk tissue' | phenotype, protocol | Combined Use of Laser Capture Microdissection and Microarray Analysis Identifies Locally Expressed Disease-Related Genes in Focal Regions of Psoriasis Vulgaris Skin Lesions |
-1 | | MRPS7 | 'chronic obstructive pulmonary disease' vs 'normal' in 'Streptococcus pneumoniae CGSP14' | disease, infect | Transcriptional profiling of primary human alveolar macrophages challenged with Streptococcus pneumoniae from patients with chronic obstructive pulmonary disease compared to healthy donors |
1 | | MRPS7 | 'Streptococcus pneumoniae CGSP14' vs 'none' in 'normal' | disease, infect | Transcriptional profiling of primary human alveolar macrophages challenged with Streptococcus pneumoniae from patients with chronic obstructive pulmonary disease compared to healthy donors |
-1 | | MRPS7 | '1 micromolar NSC319726' vs 'none' | compound | Transcription profiling by array of ovarian carcinoma TOV-112D cells treated with NSC319726 to investigate the effect on p53 targets |
